ArticleDrug design, development and therapy2026
First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03415659 (A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation/Dose-expansion Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Tumors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation/Dose-expansion Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Tumors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: HWH340 is a novel, orally administered poly(ADP-ribose) polymerase inhibitor (PARPi) developed for the treatment of solid tumors with homologous recombination repair (HRR) deficiency. It features a distinct chemical structure that has shown high selectivity and favorable PARP inhibitory and anti-tumor activities in preclinical studies. In this study, we evaluated the safety, tolerability, pharmacokinetics, and clinical profiles of HWH340 tablets in patients with advanced solid tumors to determine the recommended Phase 2 dose (RP2D). Methods: This Phase 1, open-label, multicenter study (25 centers across China) consisted of three stages: dose-escalation (n=21; 3+3 design; 20-520 mg single doses), multiple-dose escalation (n=14; 3+3 design; 100/140/200/260 mg BID), and dose-expansion (n=42; 140/200 mg BID; 28-day cycles). The dose-expansion study enrolled two cohorts: 50% of patients with germline/systemic Results: No dose-limiting toxicities were detected, and the maximum tolerated dose was not reached. The most common treatment-related severe adverse events of grades ≥3 were neutropenia (14.3%), anemia (14.3%), vomiting (11.9%), leukopenia (9.5%), thrombocytopenia (4.8%), and elevated γ-glutamyl transferase (4.8%). Among the 41 patients in the dose-expansion study with evaluable preliminary anti-tumor activity, the objective response rate (ORR) was 19.5%, and the disease control rate (DCR) was 56.1%, with a median duration of response of 4.68 months. Patients with Conclusion: HWH340 was well-tolerated and demonstrated promising preliminary anti-tumor activity in cancer patients with HRR-mutated advanced solid tumors. An integrated assessment of safety, preliminary efficacy, and pharmacokinetic profiles established 200 mg BID as the RP2D, balancing anti-tumor activity with acceptable tolerability. Given the small sample size and patient heterogeneity, these preliminary efficacy data need further confirmation by subsequent studies with larger sample sizes. Additional Resources: This study is registered with ClinicalTrials.gov, NCT03415659.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.